Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: A randomised and controlled trial

Department of Researches, National Institute of Gastroenterology, Havana, Cuba.
BMJ Open (Impact Factor: 2.27). 09/2011; 1(2):e000140. DOI: 10.1136/bmjopen-2011-000140
Source: PubMed


Article summary

Article focus

Hepatitis C virus (HCV)-related decompensated cirrhotic patients have a poor therapeutic response and reduced tolerance to the current standard of care therapy.

Therapeutic goals in these patients should be directed towards reducing liver-related morbidity and mortality, and the need for liver transplantation.

Viusid is a nutritional supplement with recognised antioxidant and immunomodulatory properties that could modulate the histological pattern of CHC, especially inflammation and fibrosis, in an attempt to halt disease progression and consequently improve liver function and liver-related morbidity and mortality, and prevent development of hepatocellular carcinoma (HCC).

Key messages

The administration of viusid to HCV-related decompensated cirrhotic patients induced a significant improvement of overall survival, a significant reduction in the disease progression and development of HCC.

The benefit of viusid was also seen in the secondary end point of worsening of the prognostic scores such as Model for End-Stage Liver Disease and Child–Pugh scores.

The viusid effects on survival and disease progression were selective for patients with advanced stage of liver disease (Child–Pugh B or C).

Viusid was well tolerated, and only minor transient adverse events such as nausea and diarrhoea were reported.

Strengths and limitations of this study

The main strength of this study was to demonstrate that viusid improves overall clinical outcomes (survival, HCC and disease progression) in cirrhotic patients who have failed to achieve sustained virological response with standard of care, and these benefits appear to be more prominent in patients with poorer liver function (Child–Pugh B or C).

The study was designed with a small sample size.

Further multicentre and large-scale studies are needed to corroborate the impact of viusid on the clinical outcomes in patients with HCV-related decompensated cirrhosis.

Download full-text


Available from: Luis Calzadilla Bertot, Apr 08, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the effects of diammonium glycyrrhizinate (Gly) on portal hypertension (PHT) in isolated portal perfused rat liver (IPPRL) with carbon tetrachloride (CCl4)-induced chronic hepatitis. PHT model was replicated with CCl4 in rats for 84 d. Model was identified by measuring the ascetic amounts, hepatic function, portal pressure in vivo, splenic index, and pathological alterations. Inducible nitric oxide synthase (iNOS) in liver was assessed by immunohistochemistry. IPPRLs were performed at d0, d28, d56, and d84. After phenylephrine-induced constriction, Gly was geometrically used to reduce PHT. Gly action was expressed as median effective concentration (EC50) and area under the curve (AUC). Underlying mechanism was exploited by linear correlation between AUC values of Gly and existed iNOS in portal triads. PHT model was confirmed with ascites, splenomegaly, serum biomarkers of hepatic injury, and elevated portal pressure. Pathological findings had shown normal hepatic structure at d0, degenerations at d28, fibrosis at d56, cirrhosis at d84 in PHT rats. Pseudo lobule ratios decreased and collagen ratios increased progressively along with PHT development. Gly does dose-dependently reduce PHT in IPPRLs with CCl4-induced chronic hepatitis. Gly potencies were increased gradually along with PHT development, characterized with its EC50 at 2.80 × 10(-10), 3.03 × 10(-11), 3.77 × 10(-11) and 4.65×10(-11) mol/L at d0, d28, d56 and d84, respectively. Existed iNOS was located at hepatocyte at d0, stellate cells at d28, stellate cells and macrophages at d56, and macrophages in portal triads at d84. Macrophages infiltrated more into portal triads and expressed more iNOS along with PHT development. AUC values of Gly were positively correlated with existed iNOS levels in portal triads. Gly reduces indirectly PHT in IPPRL with CCl4-induced chronic hepatitis. The underlying mechanisms may relate to rescue NO bioavailability from macrophage-derived peroxynitrite in portal triads.
    World Journal of Gastroenterology 09/2013; 19(36):6069-6076. DOI:10.3748/wjg.v19.i36.6069 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are patients with chronic hepatitis C who are not eligible for the current interferon-based therapies or refuse to be treated due to secondary effects. To provide information on alternative treatments for the management of these patients. A PubMed search was performed to identify relevant literature. Search terms included hepatitis C virus, anti-inflammatory treatment, antioxidant, natural products and alternative treatment, alone or in combination. Additional publications were identified using the references cited by primary and review articles. Several approaches, such as iron depletion (phlebotomy), treatment with ursodeoxycholic acid or glycyrrhizin, have anti-inflammatory and/or anti-fibrotic effects. Life interventions like weight loss, exercise and coffee consumption are associated with a biochemical improvement. Other alternatives (ribavirin monotherapy, amantadine, silibinin, vitamin supplementation, etc.) do not have any beneficial effect or need to be tested in larger clinical studies. There are therapeutic strategies and lifestyle interventions that can be used to improve liver damage in patients with chronic hepatitis C who cannot receive or refuse interferon-based treatments.
    Alimentary Pharmacology & Therapeutics 11/2013; 39(2). DOI:10.1111/apt.12562 · 5.73 Impact Factor